ANI Pharmaceuticals (NASDAQ:ANIP) Posts Earnings Results, Beats Estimates By $0.17 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) issued its earnings results on Friday. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17, FiscalAI reports. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business’s revenue was up 25.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI reported record second-quarter revenue of $266 million, up 26% year over year, with adjusted EBITDA up 32% to a record $71.6 million and operating cash flow of $56.7 million.
• The company modestly lowered 2026 Cortrophin Gel revenue guidance to $520 million-$540 million, citing first-half performance, although it maintained expectations for strong second-half growth and reaffirmed total revenue guidance of $1.08 billion-$1.14 billion.
• Cortrophin revenue rose 43% year over year to $117.1 million, while the gout-focused sales-force expansion is showing encouraging early indicators: more than 95% of new representatives generated multiple cases and over one-third of prescribers initiated at least two cases.
• Generics revenue increased 10% to $99.1 million, with 12 products launched year to date and at least 15 expected for 2026; management also highlighted that approximately 95% of revenue comes from products manufactured in the U.S.
• ILUVIEN revenue declined 16% year over year to $18.7 million, primarily due to international shipment timing, though management reaffirmed its full-year guidance and expects more detailed uveitis trial data in the fourth quarter.

ANI Pharmaceuticals Stock Down 5.3%

ANI Pharmaceuticals stock opened at $78.25 on Friday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The firm has a market cap of $1.78 billion, a P/E ratio of 16.86 and a beta of 0.44. The business has a fifty day moving average of $81.02 and a two-hundred day moving average of $79.37. ANI Pharmaceuticals has a twelve month low of $70.15 and a twelve month high of $99.50.

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 55,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the sale, the chief executive officer owned 349,889 shares of the company’s stock, valued at $27,140,889.73. This trade represents a 13.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director owned 38,432 shares in the company, valued at $3,098,772.16. This trade represents a 20.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 88,029 shares of company stock worth $6,954,472. Company insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of ANIP. Maryland State Retirement & Pension System grew its position in shares of ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after buying an additional 134 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after acquiring an additional 198 shares in the last quarter. Federation des caisses Desjardins du Quebec boosted its stake in ANI Pharmaceuticals by 0.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock valued at $3,110,000 after acquiring an additional 221 shares in the last quarter. Amundi boosted its stake in ANI Pharmaceuticals by 1.2% in the third quarter. Amundi now owns 23,918 shares of the specialty pharmaceutical company’s stock valued at $2,202,000 after acquiring an additional 285 shares in the last quarter. Finally, Alliancebernstein L.P. grew its holdings in ANI Pharmaceuticals by 1.5% in the third quarter. Alliancebernstein L.P. now owns 20,310 shares of the specialty pharmaceutical company’s stock worth $1,860,000 after purchasing an additional 300 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Canaccord Genuity Group initiated coverage on shares of ANI Pharmaceuticals in a report on Thursday, July 16th. They set a “hold” rating and a $91.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $106.83.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.